Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis.

Abrocitinib is an efficacious oral JAK 1 inhibitor recently FDA-approved for patients ≥ 18 years old with moderate-to-severe AD who have not responded to systemic medications or when contraindicated otherwise.